Eustratios Bananis
Overview
Explore the profile of Eustratios Bananis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1027
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sands B, Dubinsky M, Kotze P, Vermeire S, Panaccione R, Long M, et al.
Inflamm Bowel Dis
. 2025 Mar;
PMID: 40036804
Background: Etrasimod is an oral, once daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). This post hoc analysis of the...
2.
Afzali A, Regueiro M, Yarur A, Zabana Y, Ng S, Menon S, et al.
United European Gastroenterol J
. 2025 Feb;
PMID: 39891572
Background: Etrasimod is an oral, once-daily (q.d.), selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike the S1P receptor modulator ozanimod,...
3.
Slamon D, Dieras V, Rugo H, Harbeck N, Im S, Gelmon K, et al.
J Clin Oncol
. 2024 Jan;
42(9):994-1000.
PMID: 38252901
JCO PALOMA-2 demonstrated statistically and clinically significant improvement in progression-free survival with palbociclib plus letrozole versus placebo plus letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast...
4.
Rugo H, Im S, Joy A, Shparyk Y, Walshe J, Sleckman B, et al.
Future Oncol
. 2023 Nov;
20(1):5-16.
PMID: 37916267
What Is This Summary About?: This is a summary of an article that reported results of a study using data from two phase 3 clinical trials called "PALOMA-2" and "PALOMA-3."...
5.
Rugo H, Im S, Joy A, Shparyk Y, Walshe J, Sleckman B, et al.
Breast
. 2022 Dec;
66:324-331.
PMID: 36463643
Background: Previous analyses from the PALOMA-2 and PALOMA-3 studies showed that palbociclib (PAL) plus endocrine therapy (ET) prolongs time to first subsequent chemotherapy (TTC) versus placebo (PBO) plus ET in...
6.
Cristofanilli M, Rugo H, Im S, Slamon D, Harbeck N, Bondarenko I, et al.
Clin Cancer Res
. 2022 May;
28(16):3433-3442.
PMID: 35552673
Purpose: To conduct an updated exploratory analysis of overall survival (OS) with a longer median follow-up of 73.3 months and evaluate the prognostic value of molecular analysis by circulating tumor...
7.
Gelmon K, Walshe J, Mahtani R, Joy A, Karuturi M, Neven P, et al.
Breast
. 2021 Aug;
59:321-326.
PMID: 34388698
Objective: In the PALOMA-2 trial, palbociclib in combination with letrozole prolonged progression-free survival (PFS) and exhibited an acceptable safety profile in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative...
8.
Rugo H, Cristofanilli M, Loibl S, Harbeck N, DeMichele A, Iwata H, et al.
Oncologist
. 2021 May;
26(8):e1339-e1346.
PMID: 34037282
Background: This analysis investigated whether baseline characteristics affect the survival benefit derived from palbociclib-fulvestrant and the optimal timing of cyclin-dependent kinase 4/6 inhibitor therapy for advanced breast cancer (ABC) in...
9.
Kim J, Im S, Sim S, Bananis E, Huang X, Kim H, et al.
J Breast Cancer
. 2021 Feb;
24(1):97-105.
PMID: 33634624
In the PALOMA-3 trial, the median progression-free survival (PFS) was longer among patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with palbociclib...
10.
Rugo H, Haltner A, Zhan L, Tran A, Bananis E, Hooper B, et al.
J Comp Eff Res
. 2021 Feb;
10(6):457-467.
PMID: 33626934
Palbociclib (PAL), ribociclib (RIB) and abemaciclib (ABM), in combination with fulvestrant (FUL), are approved for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer. This study aims to determine relative...